Medical Advocates
Ethics and Infectious Diseases
  Ethical Challenges
Screening/Testing
 Refusal of Care/Services
Detention
Patient Exploitation
Compulsory Treatment
Decision-Making
Reproduction
Transplants
End-of-Life Care
Enteral Nutrition
Professional Associations
National Challenges         Sterilization
Bioterrorism                     Prison Challenges
 HIV Exceptionalism           Conflicts of Interest
Pharmaceutical Industry   Pregnancy
HIV Prevention   
Stigma
 Physician Reimbursement 
Ethics and Disease Challenges and Duties
 HIV Cure
 Ebola Virus Disease
 Executions






 
Ethics Main Page Main New and Noteworthy Home Page

Medical Advocates
Pegylated Interferons
    Hepatitis C

Peg Interferon Alfa 2a
Peg Interferon Alfa 2b
General Reports
Efficacy Studies
 Adverse Events
Quality of Life
 Adherence


 

  
Peg Interferons Main Page Main New/Newsworthy Home Page

Last Update:  August 27, 2008
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

General Reports
     
     Journal Papers, Abstracts, and Commentaries
 
 
FULL-TEXT PDF ARTICLE
 Suitable treatment period in patients with virological response during combination therapy of peginterferon and ribavirin
for chronic hepatitis C.
 Arase Y, Suzuki F, Sezaki H, et al
Intern Med. 2008;47(14):1301-7.
 Paper
 
Chronic Hepatitis C Virus Genotype 6 Infection: Response to Pegylated Interferon and Ribavirin.
 Fung J, Lai CL, Hung I, et al  
J Infect Dis. 2008 Jul 25.
 Abstract
 
Optimal dose of peginterferon and ribavirin for treatment of chronic hepatitis C.
 Gambarin-Gelwan M, Jacobson IM.
J Viral Hepat. 2008 Jul 10.
 Abstract
 
Peginterferon vs. interferon in the treatment of different HCV genotype infections in HIV patients.
Zhao S, Cheng D, Liu E, et al
Eur J Clin Microbiol Infect Dis. 2008 Jun 17.
Abstract
 
Do thyroid abnormalities detected in patients treated for HCV-related chronic hepatitis persist?
 Tarantino G, Gagliardi G, Conca P.  
Int J Immunopathol Pharmacol. 2008 Apr-Jun;21(2):467-9.
 Abstract
 
Early and Accurate Prediction of Peg-IFNs/Ribavirin Therapy Outcome in the Individual Patient
With Chronic Hepatitis C by Modeling the Dynamics of the Infected Cells.
Colombatto P, Ciccorossi P, Maina A, et al
Clin Pharmacol Ther. 2008 Mar 12
 Abstract
 
Pegylated interferon therapy in chronic hepatitis C: lights and shadows of an innovative
treatment.
Almasio PL, Cottone C, D’Angelo F.
Dig Liver Dis. 2007 Sep;39 Suppl 1:S88-95.
Abstract
 
Mutations in the interferon sensitivity determining region (NS5A aa 2209-2248) in patients with
hepatitis C 1b infection and correlating response to combined therapy of pegylated interferon
and ribavirin.
 Yen YH, Hung CH, Hu TH, et al  
 Aliment Pharmacol Ther. 2007 Oct 26;
 Abstract
 
Haematological support during peg-interferon therapy for HCV-infected haemophiliacs improves
virological outcomes.
Kevans D, Farrell G, Hopkins S, et al
 Haemophilia. 2007 Sep;13(5):593-598.
Abstract 
 
Infant of 22 months of age with no anomalies born from a HCV- and HIV-infected mother
under treatment with pegylated interferon, ribavirin and antiretroviral therapy during the first
16 weeks of pregnancy.
 Labarga P, Pinilla J, Cachorro I, Del Prado YR.
 Reprod Toxicol. 2007 Jul 7;
Abstract 
 
Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic
hepatitis C: a systematic review and economic evaluation.
 Shepherd J, Jones J, Hartwell D, et al
 Health Technol Assess. 2007 Mar;11(11):1-224
 Abstract
 
Emerging strategies for pegylated interferon combination therapy.
 Schiff ER.  
Nat Clin Pract Gastroenterol Hepatol. 2007 Jan;4 Suppl 1:S17-21.
 Abstract
 
Pegylated interferon plus ribavirin for chronic hepatitis C: the role of combination therapy today,
tomorrow and in the future.
Ferenci P.
Minerva Gastroenterol Dietol. 2006 Jun;52(2):157-74
 Abstract